疫苗学《Vaccines》——6th Edition by (美)普洛特金

rojjer

Vaccines, 6th Edition

& j; o/ V2 U) A' J4 L4 ZApply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice.

http://yun.baidu.com/share/link?shareid=2079860221&uk=3810996606

3 {) ^! ^! {7 m# T3 kSECTION 1: General aspects of vaccination
1 A short history of vaccination 1
2 Vaccine immunology 14
3 The vaccine industry 33
4 Vaccine manufacturing 44
" J8 a6 x4 M, J- ]: t5 Evolution of adjuvants across the centuries 58
- z6 ^: L4 |( P6 Vaccine additives and manufacturing residuals in the United States:
licensed vaccines 71
0 ?1 @3 F% p/ v' D; V" _% N7 Passive immunization 80
$ y+ }/ S1 V' V  k* L8 General immunization practices 88
/ K, y( p# ]- W& a3 _SECTION 2: Licensed vaccines
9 Adenovirus vaccines 113
10 Anthrax vaccines 127
11 Cholera vaccines 141
12 Diphtheria toxoid 153
13 Haemophilus influenzae vaccines 167
! ]8 U# c1 z) L2 ]# @) ^14 Hepatitis A vaccines 183
$ q- T$ F9 g! H6 S# j+ ]! P15 Hepatitis B vaccines 205
9 v1 ?, o; I/ I! T' Z16 Human papillomavirus vaccines 235
2 }: @0 t. t0 _' w. ]% l17 Inactivated influenza vaccines 257
& H: [5 f1 p7 [6 A3 q% k: G18 Influenza vaccine-live 294
19 Japanese encephalitis vaccines 312
20 Measles vaccines 352
21 Meningococcal vaccines 388
22 Mumps vaccine 419
  A7 {# ]5 U' J+ e6 p23 Pertussis vaccines . 447
24 Plague vaccines 493
! q9 b' q9 A& |( {2 B3 j25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504
26 Pneumococcal polysaccharide vaccines 542
! h, |* _. F6 G) y9 l1 a27 Poliovirus vaccine-inactivated . 573
7 Z7 \, p; [* x+ |7 `* H28 Poliovirus vaccine-live 598
8 L5 \, _- b) h# |# i* k  n! r4 ?29 Rabies vaccines .646
# \) m# K# a5 t+ Z30 Rotavirus vaccines . 669
' u' I3 L  G* U4 d& x6 x31 Rubella vaccine 688
4 T+ d0 ^& T9 G+ @( |32 Smallpox and vaccinia 718
33 Tetanus toxoid 746
! R$ g1 k) q9 z3 _. ]5 T34 Tick-borne encephalitis virus vaccines 773
35 Tuberculosis vaccines 789
36 Typhoid fever vaccines 812
4 l7 w# p9 q% Q37 Varicella vaccine 837
38 Yellow fever vaccine 870
39 Zoster vaccine 969
40 Combination vaccines 981
SECTION 3: Vaccines in development and new vaccine strategies
+ S5 F6 s, S( s5 o41 Biodefense and special pathogen vaccines 1008
42 Therapeutic cancer vaccines 1018
8 S1 y% U4 W  h" O43 Cytomegalovirus vaccines 1032
; N+ E- ?5 z# L' h4 S. A3 D. r# q44 Dengue vaccines 1042
3 ?; o+ I, x" ^" e3 m2 P" P! R) p0 S, h3 c45 Diarrhea caused by bacteria 1052
* P  A3 e3 K4 E! X: |46 Ebola vaccine 1060
47 Epstein-Barr virus vaccines 1068
( D  l( r. N/ x" t0 X48 Hepatitis C vaccines 1074
; `! i* }5 L% Z1 z$ ^49 Hepatitis E vaccines 1085
50 Herpes simplex virus vaccines 1090
51 Human immunodeficiency virus vaccines 1097
52 Lyme disease vaccines 1122
/ P: [2 B: T$ E# ~) X2 O53 Malaria vaccines 1133
54 Noninfectious disease vaccines 1138
55 Respiratory syncytial virus and parainfluenza virus vaccines 1146
* t: k$ ?5 S0 n56 Parasitic disease vaccines 1154
9 H! x! ?* Z. s: u' C5 H; _; c57 Staphylococcus aureus vaccines 1161
58 Streptococcus group A vaccines 1169
) M0 d: A% b% M7 E( O59 Streptococcus group B vaccines 1176
. n4 P( n0 r2 P" e3 k- k60 Technologies for making new vaccines 1182
61 Alternative vaccine delivery methods 1200
' v# P2 O, Y6 R62 The development of gene-based vectors for immunization 1232
SECTION 4: Vaccination of special groups
63 Vaccination of immunocompromised hosts 1243
64 Vaccination of human immunodeficiency virus-infected persons 1257
/ K& {1 k! u1 x9 J5 n8 S65 Vaccines for international travel 1270
* P' L- i3 E+ c2 S) A4 `2 y$ a66 Vaccines for health care personnel 1290
SECTION 5: Public health and regulatory issues
67 Immunization in the United States 1310
4 q6 c0 y2 i( O68 Immunization in Europe . 1334
5 O1 s* c: u; c69 Immunization in the Asia-Pacific region 1353
( w1 r: a* @5 j9 d' V& a: D70 Immunization in developing countries 1369
71 Community immunity 1395
* O+ t" _$ Z5 k' E6 o4 a# `1 a72 Economic analyses of vaccine policies 1413
) q; s$ |1 d- K; F% g73 Regulation and testing of vaccines 1427
) F/ B9 x: `6 N" K) N- R) I  C1 }74 Regulation of vaccines in Europe 1447
75 Regulation of vaccines in developing countries 1454
, N5 y- d' V  W: [& _76 Vaccine safety 1464
; V' [6 V# l  E$ I# m: v77 Legal issues . 1481
; N) V8 Z# a" L* e78 Ethics 1508


$ c% Q6 p! v4 t7 Y7 a( @

casarett

Vaccines, 6e, 2012
$ w1 C4 V6 n! C  J
: j$ x6 L' U4 I, Q; {Hardcover: 1570 pages
Publisher: Saunders; 6 edition (October 30, 2012)
Language: English
ISBN-10: 1455700908
% ]' a8 P. z! s+ W  H7 ?1 W0 N! j; [! iSize: 52.3mb (original pdf)

2013 BMA Medical Book Awards Highly Commended in Public Health!
Apply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice!

9 W5 t" G+ g2 S7 X* {; bGain a complete understanding of each disease, including clinical characteristics, microbiology, pathogenesis, diagnosis, and treatment, as well as epidemiology and public health and regulatory issues.
5 b+ |. e2 a7 z  k9 `, MUpdate your knowledge of both existing vaccines and vaccines currently in the research and development stage.
/ x, J+ @+ [6 P/ DGet complete answers on each vaccine, including its stability, immunogenicity, efficacy, duration of immunity, adverse events, indications, contraindications, precautions, administration with other vaccines, and disease-control strategies.
1 N; R6 \4 G( x3 qAnalyze the cost-benefit and cost-effectiveness of different vaccine options.
$ e+ ]% r# j  u0 r% nClearly visualize concepts and objective data through an abundance of tables and figures.
. o! a6 C. I) t) ^6 P& G, TPerform seamless searches of the complete text online, access all the references, and download all the images at www.expertconsult.com.
4 J3 g! s# O2 j, ?2 U4 h, lMake optimal use of the latest vaccines for pneumococcal disease, rotavirus, human papillomavirus, herpes zoster, meningococcal disease, and much more.
Stay at the forefront of new developments with completely updated chapters on malaria and HIV vaccines, a new chapter on vaccine regulations across the world, and many other revisions throughout.
0 P  Q) J( [, J( d. H, A
! ^$ o2 }. d8 H# V7 F; n  O1 zDownload link: http://pan.baidu.com/s/1i5NxwLR
' E4 M, }" S  ]Code for downloading: dv96
; s& a4 W4 B( c2 a" `3 s

rojjer

Vaccines, 6th Edition
. K/ `2 P( E( o+ e+ M4 |
Apply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice.

http://yun.baidu.com/share/link? ... 1&uk=3810996606
4 F; n$ }5 q0 C
% q2 Z) D* j- S7 H( `SECTION 1: General aspects of vaccination
1 A short history of vaccination 1
6 }+ J/ k/ Q3 ?& a- x8 {3 t2 Vaccine immunology 14
3 The vaccine industry 33
4 Vaccine manufacturing 44
5 Evolution of adjuvants across the centuries 58
8 c$ H1 A  z+ s  O5 E  E6 Vaccine additives and manufacturing residuals in the United States:
licensed vaccines 71
7 Passive immunization 80
8 General immunization practices 88
SECTION 2: Licensed vaccines
* G1 ^6 }4 S0 O& a9 Adenovirus vaccines 113
10 Anthrax vaccines 127
0 z! Y; c# R2 y, f5 R+ j2 r11 Cholera vaccines 141
. _* \/ y2 Q5 @5 g7 ?12 Diphtheria toxoid 153
- M& s) g/ x5 u2 K13 Haemophilus influenzae vaccines 167
14 Hepatitis A vaccines 183
15 Hepatitis B vaccines 205
" ]6 y6 L" [8 X16 Human papillomavirus vaccines 235
17 Inactivated influenza vaccines 257
+ U  ?% Y( }- g- [18 Influenza vaccine-live 294
$ Y9 ?4 D& p' [4 s. i; Q# g19 Japanese encephalitis vaccines 312
# m+ @9 Y: W4 e# N7 {; W& T# K: K20 Measles vaccines 352
21 Meningococcal vaccines 388
22 Mumps vaccine 419
23 Pertussis vaccines . 447
24 Plague vaccines 493
0 b) k7 E8 v7 F9 o3 K# a25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504
26 Pneumococcal polysaccharide vaccines 542
27 Poliovirus vaccine-inactivated . 573
1 b- l- [& S! M! b$ v( `* H28 Poliovirus vaccine-live 598
; ]6 g& S5 y/ H8 D9 Q# I1 h& I4 [29 Rabies vaccines .646
- ^! U! f) v# C$ R7 [  }* f30 Rotavirus vaccines . 669
31 Rubella vaccine 688
8 {2 [& }4 q) E3 E9 k0 N32 Smallpox and vaccinia 718
33 Tetanus toxoid 746
& }" Z  l6 E* `! Q" V5 G34 Tick-borne encephalitis virus vaccines 773
35 Tuberculosis vaccines 789
36 Typhoid fever vaccines 812
3 C& h- g! M& v9 g; a37 Varicella vaccine 837
3 X9 n8 r% R/ j38 Yellow fever vaccine 870
39 Zoster vaccine 969
40 Combination vaccines 981
0 h2 L: y; E; e+ |- V9 ]1 k  F9 rSECTION 3: Vaccines in development and new vaccine strategies
5 n$ v& I) k- y6 Z41 Biodefense and special pathogen vaccines 1008
42 Therapeutic cancer vaccines 1018
  S: ]; l/ b# s0 W, ~43 Cytomegalovirus vaccines 1032
44 Dengue vaccines 1042
; y" E) d6 c- s% h) B45 Diarrhea caused by bacteria 1052
46 Ebola vaccine 1060
47 Epstein-Barr virus vaccines 1068
1 B5 y2 Z2 i7 d. B! K  G' S+ H48 Hepatitis C vaccines 1074
49 Hepatitis E vaccines 1085
# f$ @6 U8 m7 |50 Herpes simplex virus vaccines 1090
9 V5 i* Y4 r6 S% I. f4 ^) h$ Y51 Human immunodeficiency virus vaccines 1097
52 Lyme disease vaccines 1122
$ G$ \* r- X1 Z4 L# f9 H53 Malaria vaccines 1133
54 Noninfectious disease vaccines 1138
55 Respiratory syncytial virus and parainfluenza virus vaccines 1146
56 Parasitic disease vaccines 1154
( T" ^, a: _' |% Y57 Staphylococcus aureus vaccines 1161
6 R/ n7 t% a8 {58 Streptococcus group A vaccines 1169
5 |  Y1 C4 s4 n- P5 R: B. g59 Streptococcus group B vaccines 1176
60 Technologies for making new vaccines 1182
61 Alternative vaccine delivery methods 1200
62 The development of gene-based vectors for immunization 1232
SECTION 4: Vaccination of special groups
* i& ~- X$ D' V; ^63 Vaccination of immunocompromised hosts 1243
9 Q1 |" [' C* f$ G64 Vaccination of human immunodeficiency virus-infected persons 1257
65 Vaccines for international travel 1270
( f3 V2 R) P9 @: b  Y! A. D# j66 Vaccines for health care personnel 1290
6 V2 H+ M0 g* nSECTION 5: Public health and regulatory issues
67 Immunization in the United States 1310
- e: A7 |5 T9 A- M1 m' ]68 Immunization in Europe . 1334
5 U4 |7 ?* N+ D( b9 q! @; j69 Immunization in the Asia-Pacific region 1353
: J1 \$ r" H% v& p/ Y8 {70 Immunization in developing countries 1369
71 Community immunity 1395
- L' `" P9 M9 `- b72 Economic analyses of vaccine policies 1413
) ]3 W5 [2 Q: \  K- G73 Regulation and testing of vaccines 1427
74 Regulation of vaccines in Europe 1447
75 Regulation of vaccines in developing countries 1454
76 Vaccine safety 1464
77 Legal issues . 1481
78 Ethics 1508
) v, t7 j4 @4 J4 I# X, L
4 d1 M. k! j+ ~$ P- }& ?. b

zhpu2008

怎么看不到相关下载呀

zhpu2008

谢谢分享

salina

非常感谢